Investor

AIMEDICS mission is to provide a safer nights sleep for people with insulin requiring diabetes.

Worldwide, there are 56 million people with diabetes using insulin. On average, each one of these people will have 1-2 severe hypoglycaemia (critically low blood glucose) events per year.

AIMEDICS' HypoMon product non-invasively and accurately detects these life threatening events during the night and alerts the user or carer.

AIMEDICS has independantly validated a significant clinical and consumer need for the HypoMon

To learn more about AIMEDICS, please click on the below links:

• Company Profile 
• Board Profile
• News & Updates (complete list)

If you would like further information about AIMEDICS investment opportunities, please email investor@aimedics.com.